List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6193056/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Breast Radiation Therapy–Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. International Journal of Radiation Oncology Biology Physics, 2022, 112, 437-444.	0.8	6
2	Contemporary Outcomes After Multimodality Therapy in Patients With Breast Cancer Presenting With Ipsilateral Supraclavicular Node Involvement. International Journal of Radiation Oncology Biology Physics, 2022, 112, 66-74.	0.8	9
3	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. Npj Breast Cancer, 2022, 8, 12.	5.2	6
4	Chemotherapy Triggers T Cells to Remodel the Extracellular Matrix and Promote Metastasis. Cancer Research, 2022, 82, 197-198.	0.9	1
5	Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Research and Treatment, 2022, 192, 235-243.	2.5	17
6	Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer. Advances in Radiation Oncology, 2022, 7, 100877.	1.2	4
7	Trends in Sentinel Lymph Node Biopsies in Patients With Inflammatory Breast Cancer in the US. JAMA Network Open, 2022, 5, e2148021.	5.9	1
8	Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.8	2
9	NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. Journal of the National Cancer Institute, 2022, 114, 579-591.	6.3	25
10	Immediate Breast Reconstruction in Inflammatory Breast Cancer: Are We There Yet?. Annals of Surgical Oncology, 2022, , .	1.5	3
11	Inflammatory Breast Cancer: The Cytokinome of Post-Mastectomy Wound Fluid Augments Proliferation, Invasion, and Stem Cell Markers. Current Issues in Molecular Biology, 2022, 44, 2730-2744.	2.4	1
12	A multiâ€institutional prediction model to estimate the risk of recurrence and mortality after mastectomy for <scp>T1â€2N1</scp> breast cancer. Cancer, 2022, 128, 3057-3066.	4.1	7
13	Proton radiotherapy for breast cancer. , 2021, , 115-125.e3.		0
14	Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a Planned Interim Analysis of a Prospective Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 441-448.	0.8	19
15	Anatomy and physiology of the sentinel lymph nodes of the upper extremity: Implications for axillary reverse mapping in breast cancer. Journal of Surgical Oncology, 2021, 123, 846-853.	1.7	4
16	Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. Communications Biology, 2021, 4, 72.	4.4	29
17	The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 4265-4274.	1.5	11
18	Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells. Journal of Visualized Experiments, 2021, , .	0.3	3

#	Article	IF	CITATIONS
19	Prophylactic cranial irradiation reduces the incidence of brain metastasis in a mouse model of metastatic, HER2-positive breast cancer. Genes and Cancer, 2021, 12, 28-38.	1.9	2
20	Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum. Translational Oncology, 2021, 14, 101026.	3.7	13
21	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. Genome Medicine, 2021, 13, 70.	8.2	8
22	Association of statin use with clinical outcomes in patients with triple-negative breast cancer Journal of Clinical Oncology, 2021, 39, 523-523.	1.6	0
23	Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology, 2021, 28, 8610-8621.	1.5	7
24	Genomically Guided Breast Radiation Therapy: A Review of the Current Data and Future Directions. Advances in Radiation Oncology, 2021, 6, 100731.	1.2	7
25	Inflammatory Breast Cancer at the Extremes of Age. Annals of Surgical Oncology, 2021, 28, 5626-5634.	1.5	5
26	Inflammatory breast cancer appearance at presentation is associated with overall survival. Cancer Medicine, 2021, 10, 6261-6272.	2.8	10
27	Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis. Npj Breast Cancer, 2021, 7, 87.	5.2	7
28	Association of statin use with clinical outcomes in patients with tripleâ€negative breast cancer. Cancer, 2021, 127, 4142-4150.	4.1	22
29	Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804. Journal of Clinical Oncology, 2021, 39, 3574-3582.	1.6	48
30	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. Molecular Oncology, 2021, 15, 2752-2765.	4.6	19
31	Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2021, 111, 360-370.	0.8	12
32	Outcomes after breast radiotherapy in a diverse patient cohort with a germline BRCA1/2 mutation. International Journal of Radiation Oncology Biology Physics, 2021, , .	0.8	1
33	How should radiation be done for inflammatory breast cancer patients?—a narrative review of modern literature. Chinese Clinical Oncology, 2021, 10, 60-60.	1.2	0
34	Why diagnosing inflammatory breast cancer is hard and how to overcome the challenges: a narrative review. Chinese Clinical Oncology, 2021, 10, 58-58.	1.2	1
35	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	7.1	51
36	Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast. JAMA Oncology, 2020, 6, 75.	7.1	60

#	Article	IF	CITATIONS
37	Building momentum for subsets of patients with advanced triple-negative breast cancer. Lancet Oncology, The, 2020, 21, 3-5.	10.7	6
38	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. Advances in Radiation Oncology, 2020, 5, 567-572.	1.2	12
39	Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Annals of Surgical Oncology, 2020, 27, 4603-4612.	1.5	12
40	Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers, 2020, 12, 3105.	3.7	1
41	Understanding the Intersection of Working from Home and Burnout to Optimize Post-COVID19 Work Arrangements in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 108, 370-373.	0.8	35
42	NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. Cancers, 2020, 12, 3711.	3.7	20
43	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer, 2020, 20, 430.	2.6	4
44	IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2. Toxicology and Applied Pharmacology, 2020, 401, 115092.	2.8	14
45	In vitro vascularized tumor platform for modeling tumorâ€vasculature interactions of inflammatory breast cancer. Biotechnology and Bioengineering, 2020, 117, 3572-3590.	3.3	16
46	Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy and Oncology, 2020, 148, 157-166.	0.6	352
47	Exclusion of Men from Randomized Phase III Breast Cancer Clinical Trials. Oncologist, 2020, 25, e990-e992.	3.7	15
48	Abstract P3-01-10: Ndrg1-egfr axis in inflammatory breast cancer tumorigenesis and brain metastasis. , 2020, , .		4
49	Molecular Predictive and Prognostic Markers in Locoregional Management. Journal of Clinical Oncology, 2020, 38, 2310-2320.	1.6	10
50	An inflammatory imposter: Three cases of Mullerian carcinoma appearing as inflammatory breast cancer. Breast Journal, 2020, 26, 1022-1024.	1.0	0
51	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. Journal of Cancer, 2019, 10, 3344-3351.	2.5	19
52	Dr Eleanor D. Montague, 1926-2018. International Journal of Radiation Oncology Biology Physics, 2019, 104, 972-973.	0.8	0
53	The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2019, 105, 698-712.	0.8	69
54	Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Practical Radiation Oncology, 2019, 9, 402-409.	2.1	8

#	Article	IF	CITATIONS
55	The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. Journal of Cancer, 2019, 10, 2635-2642.	2.5	3
56	Mixture theory modeling for characterizing solute transport in breast tumor tissues. Journal of Biological Engineering, 2019, 13, 46.	4.7	7
57	Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer. Breast Cancer Research and Treatment, 2019, 176, 545-556.	2.5	16
58	Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. International Journal of Radiation Oncology Biology Physics, 2019, 104, 574-581.	0.8	9
59	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	3.4	70
60	Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model. Oncologist, 2019, 24, 1322-1330.	3.7	6
61	Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. Practical Radiation Oncology, 2019, 9, e4-e13.	2.1	13
62	NRG-BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer (NCT02364557) Journal of Clinical Oncology, 2019, 37, TPS1117-TPS1117.	1.6	26
63	Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: A large, single-institutional experience Journal of Clinical Oncology, 2019, 37, 1502-1502.	1.6	0
64	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Research and Treatment, 2018, 169, 615-623.	2.5	12
65	A component of lobular carcinoma in clinically lymph node–negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer. Advances in Radiation Oncology, 2018, 3, 252-257.	1.2	6
66	Material matters: Analysis of density uncertainty in 3D printing and its consequences for radiation oncology. Medical Physics, 2018, 45, 1614-1621.	3.0	55
67	Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer, 2018, 124, 2299-2305.	4.1	11
68	Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1034-1043.	0.8	96
69	Inflammatory breast cancer biology: the tumour microenvironment is key. Nature Reviews Cancer, 2018, 18, 485-499.	28.4	235
70	In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines. Veterinary and Comparative Oncology, 2018, 16, 148-158.	1.8	10
71	Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory BreastÂCancer. Clinical Breast Cancer, 2018, 18, e73-e77.	2.4	28
72	Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 23-37.	0.8	48

#	Article	IF	CITATIONS
73	Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. Journal of Clinical Oncology, 2018, 36, 3495-3503.	1.6	54
74	Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. Journal of Clinical Oncology, 2018, 36, 1317-1322.	1.6	60
75	Design, fabrication, and validation of patient-specific electron tissue compensators for postmastectomy radiation therapy. Physics and Imaging in Radiation Oncology, 2018, 8, 38-43.	2.9	5
76	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS ONE, 2018, 13, e0204372.	2.5	16
77	Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. PLoS ONE, 2018, 13, e0204513.	2.5	34
78	Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 568-577.	0.8	19
79	Inflammatory Breast Cancer. Surgical Clinics of North America, 2018, 98, 787-800.	1.5	63
80	Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. Breast Cancer Research and Treatment, 2018, 171, 283-293.	2.5	15
81	Gene set analysis of post-lactational mammary gland involution gene signatures in inflammatory and triple-negative breast cancer. PLoS ONE, 2018, 13, e0192689.	2.5	20
82	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. Journal of Cancer, 2018, 9, 1437-1447.	2.5	84
83	Analysis of Hierarchical Organization in Gene Expression Networks Reveals Underlying Principles of Collective Tumor Cell Dissemination and Metastatic Aggressiveness of Inflammatory Breast Cancer. Frontiers in Oncology, 2018, 8, 244.	2.8	15
84	Proton Partial Breast Irradiation: Detailed Description of Acute Clinico-Radiologic Effects. Cancers, 2018, 10, 111.	3.7	6
85	Association of Transforming Growth Factor β Polymorphism Câ^ 509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer. JAMA Oncology, 2018, 4, 1751.	7.1	34
86	Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Letters, 2018, 431, 54-63.	7.2	50
87	Reply to â€~A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. Breast, 2018, 39, 148-149.	2.2	2
88	Between a Rock and a Hard Place. International Journal of Radiation Oncology Biology Physics, 2018, 101, 266.	0.8	0
89	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncology, 2018, 4, 1207.	7.1	56
90	Canine cell line, <scp>IPC</scp> â€366, as a good model for the study of inflammatory breast cancer. Veterinary and Comparative Oncology, 2017, 15, 980-995.	1.8	12

#	Article	IF	CITATIONS
91	Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Research and Treatment, 2017, 163, 263-272.	2.5	27
92	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Research and Treatment, 2017, 164, 57-67.	2.5	31
93	Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgery, 2017, 265, 574-580.	4.2	21
94	A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 777-783.	0.8	30
95	Novel therapeutic strategies in the treatment of triple-negative breast cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 493-511.	3.2	58
96	Use of regional nodal irradiation and its association with survival for women with high-risk, early stage breast cancer: A National Cancer Database analysis. Advances in Radiation Oncology, 2017, 2, 291-300.	1.2	15
97	Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system. Lancet Oncology, The, 2017, 18, e228-e232.	10.7	74
98	Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer, 2017, 123, 2618-2625.	4.1	11
99	NRG Oncology–Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1028-1035.	0.8	49
100	Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Research and Treatment, 2017, 162, 201-215.	2.5	96
101	Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Annals of Surgical Oncology, 2017, 24, 2981-2988.	1.5	30
102	(P015) Radiotherapy After Skin-Sparing Mastectomy and Placement of a Tissue Expander: Effectiveness of a Coordinated, Multidisciplinary Approach. International Journal of Radiation Oncology Biology Physics, 2017, 98, E19.	0.8	2
103	A 10-Year Experience with Mastectomy and Tissue Expander Placement to Facilitate Subsequent Radiation and Reconstruction. Annals of Surgical Oncology, 2017, 24, 2965-2971.	1.5	20
104	In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery― the argument against breast conservation and sentinel lymph node biopsy in IBC. Breast Cancer Research and Treatment, 2017, 165, 779-781.	2.5	4
105	Inflammatory breast cancer: a model for investigating cluster-based dissemination. Npj Breast Cancer, 2017, 3, 21.	5.2	117
106	Effect of statins on breast cancer recurrence and mortality: a review. Breast Cancer: Targets and Therapy, 2017, Volume 9, 559-565.	1.8	47
107	Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. Journal of Cancer, 2017, 8, 2026-2032.	2.5	25
108	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. Journal of Cancer, 2017, 8, 3607-3614.	2.5	15

#	Article	IF	CITATIONS
109	DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. Journal of Cancer, 2017, 8, 2653-2662.	2.5	38
110	Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. Journal of Cancer, 2017, 8, 1726-1732.	2.5	5
111	Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer Journal of Clinical Oncology, 2017, 35, 11501-11501.	1.6	2
112	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget, 2017, 8, 35656-35668.	1.8	44
113	EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget, 2017, 8, 67904-67917.	1.8	40
114	Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. Journal of Cancer, 2016, 7, 1095-1104.	2.5	73
115	Steroid Tumor Environment in Male and Female Mice Model of Canine and Human Inflammatory Breast Cancer. BioMed Research International, 2016, 2016, 1-7.	1.9	13
116	Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory BreastÂCancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1218-1225.	0.8	6
117	Longitudinal analysis of patientâ€reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated wholeâ€breast irradiation. Cancer, 2016, 122, 2886-2894.	4.1	29
118	Implementing a Real-Time Electronic Data Capture System to Improve Clinical Documentation in Radiation Oncology. Journal of the American College of Radiology, 2016, 13, 401-407.	1.8	17
119	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw026.	6.3	70
120	Proton Radiation Biology Considerations for Radiation Oncologists. International Journal of Radiation Oncology Biology Physics, 2016, 95, 59-61.	0.8	17
121	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 637-644.	0.8	1
122	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12780-12785.	7.1	31
123	Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Research, 2016, 18, 97.	5.0	28
124	Cancer Stem Cells. Recent Results in Cancer Research, 2016, 198, 25-44.	1.8	7
125	Cholesterol and Radiosensitivity. Current Breast Cancer Reports, 2016, 8, 32-39.	1.0	3
126	Proton Partial-Breast Irradiation for Early-Stage Cancer: Is It Really So Costly?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 49-51.	0.8	15

#	Article	IF	CITATIONS
127	Computational Modeling of Micrometastatic Breast Cancer Radiation Dose Response. International Journal of Radiation Oncology Biology Physics, 2016, 96, 179-187.	0.8	9
128	Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes and Control, 2016, 27, 359-366.	1.8	38
129	MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity inÂBreast Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 791-799.	0.8	21
130	NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer Journal of Clinical Oncology, 2016, 34, TPS1098-TPS1098.	1.6	7
131	Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget, 2016, 7, 82482-82492.	1.8	78
132	Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget, 2016, 7, 28329-28339.	1.8	54
133	Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer Journal of Clinical Oncology, 2016, 34, 1087-1087.	1.6	3
134	Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thrombosis and Haemostasis, 2015, 113, 593-598.	3.4	30
135	Prognosis for patients with metastatic breast cancer who achieve a noâ€evidenceâ€ofâ€disease status after systemic or local therapy. Cancer, 2015, 121, 4324-4332.	4.1	34
136	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 242-247.	1.3	26
137	Differential Effect of Phosphorylation-Defective Survivin on Radiation Response in Estrogen Receptor-Positive and -Negative Breast Cancer. PLoS ONE, 2015, 10, e0120719.	2.5	3
138	Stromal Cells Derived from Visceral and Obese Adipose Tissue Promote Growth of Ovarian Cancers. PLoS ONE, 2015, 10, e0136361.	2.5	35
139	Steroid hormone secretion in inflammatory breast cancer cell lines. Hormone Molecular Biology and Clinical Investigation, 2015, 24, 137-145.	0.7	11
140	Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. International Journal of Radiation Oncology Biology Physics, 2015, 93, 102-110.	0.8	3
141	HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research, 2015, 17, 149.	5.0	42
142	Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Research, 2015, 17, 2.	5.0	36
143	Local-Regional Treatment of the Patient With Inflammatory Breast Cancer. Current Breast Cancer Reports, 2015, 7, 37-42.	1.0	0
144	Pregnancy and Parenthood in Radiation Oncology, Views and Experiences Survey (PROVES): Results of a Blinded Prospective Trainee Parenting and Career Development Assessment. International Journal of Radiation Oncology Biology Physics, 2015, 92, 516-524.	0.8	55

#	Article	IF	CITATIONS
145	Proton partial breast irradiation in the supine position: Treatment description and reproducibility of a multibeam technique. Practical Radiation Oncology, 2015, 5, e283-e290.	2.1	8
146	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation. JAMA Oncology, 2015, 1, 931.	7.1	216
147	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment, 2015, 152, 407-416.	2.5	68
148	Breast Cancer Stem Cell Correlates as Predicative Factors for Radiation Therapy. Seminars in Radiation Oncology, 2015, 25, 251-259.	2.2	9
149	High-Density and Very-Low-Density LipoproteinÂHave Opposing Roles in Regulating Tumor-Initiating Cells and Sensitivity to Radiation in Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 91, 1072-1080.	0.8	33
150	Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Research, 2015, 17, 42.	5.0	49
151	The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. SpringerPlus, 2015, 4, 36.	1.2	14
152	Should Surgery Referral be Standard Practice in Metastatic Inflammatory Breast Cancer?. Annals of Surgical Oncology, 2015, 22, 2466-2467.	1.5	3
153	Receptor Status Change From Primary to Residual Breast Cancer After Neoadjuvant Chemotherapy and Analysis of Survival Outcomes. Clinical Breast Cancer, 2015, 15, 153-160.	2.4	33
154	Inflammatory breast cancer: unique biological and therapeutic considerations. Lancet Oncology, The, 2015, 16, e568-e576.	10.7	51
155	Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. Radiotherapy and Oncology, 2015, 117, 308-314.	0.6	23
156	Breast Radiation Therapy—Sometimes Less May Be More. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1-3.	0.8	2
157	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Research and Treatment, 2015, 154, 495-508.	2.5	52
158	Establishment and Characterization of a New Cell Line of Canine Inflammatory Mammary Cancer: IPC-366. PLoS ONE, 2015, 10, e0122277.	2.5	31
159	Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PLoS ONE, 2015, 10, e0132710.	2.5	121
160	High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer. PLoS ONE, 2014, 9, e83113.	2.5	91
161	Aldehyde Dehydrogenase1 Immunohistochemical Staining in Primary Breast Cancer Cells Independently Predicted Overall Survival But Did Not Correlate with the Presence of Circulating or Disseminated Tumors Cells. Journal of Cancer, 2014, 5, 360-367.	2.5	11
162	Web based pathology assessment in RTOG 98-04. Journal of Clinical Pathology, 2014, 67, 777-780.	2.0	5

#	Article	IF	CITATIONS
163	Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. Cancer, 2014, 120, 1319-1328.	4.1	57
164	miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nature Communications, 2014, 5, 5671.	12.8	148
165	Radiation therapy for inflammatory breast cancer: technical considerations and diverse clinical scenarios. Breast Cancer Management, 2014, 3, 43-52.	0.2	4
166	Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Annals of Oncology, 2014, 25, 384-391.	1.2	102
167	Patched Targeting Peptides for Imaging and Treatment of Hedgehog Positive Breast Tumors. BioMed Research International, 2014, 2014, 1-9.	1.9	6
168	ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome. Breast Diseases, 2014, 25, 47-48.	0.0	0
169	Shortened Radiation Therapy Schedules for Early-Stage Breast Cancer: A Review of Hypofractionated Whole-Breast Irradiation and Accelerated Partial Breast Irradiation. Breast Journal, 2014, 20, 131-146.	1.0	17
170	Aldehyde Dehydrogenase 1 Expression in Inflammatory Breast Cancer as Measured by Immunohistochemical Staining. Clinical Breast Cancer, 2014, 14, e81-e88.	2.4	17
171	Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of Oncology, 2014, 25, 358-365.	1.2	82
172	Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. Stem Cells Translational Medicine, 2014, 3, 849-856.	3.3	69
173	Prospective Analysis of Association between Statin Use and Breast Cancer Risk in the Women's Health Initiative. Breast Diseases, 2014, 25, 125.	0.0	0
174	ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nature Cell Biology, 2014, 16, 864-875.	10.3	367
175	Postmastectomy Radiation Therapy for Inflammatory Breast Cancer: Is More Better?. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1004-1005.	0.8	13
176	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 58.	8.6	23
177	Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. SpringerPlus, 2014, 3, 166.	1.2	20
178	Implementation of the American College of Surgeons Oncology Group Z1071 Trial Data in Clinical Practice: Is There a Way Forward for Sentinel Lymph Node Dissection in Clinically Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?. Annals of Surgical Oncology, 2014, 21, 2468-2473	1.5	53
179	Statistical Modeling Approach to Quantitative Analysis of Interobserver Variability in Breast Contouring. International Journal of Radiation Oncology Biology Physics, 2014, 89, 214-221.	0.8	22
180	Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: Implications for targeting the undissected axilla. Practical Radiation Oncology, 2014, 4, 116-122.	2.1	7

#	Article	IF	CITATIONS
181	Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. International Journal of Radiation Oncology Biology Physics, 2014, 89, 392-398.	0.8	126
182	Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiation Oncology, 2013, 8, 13.	2.7	30
183	Statin use in primary inflammatory breast cancer: a cohort study. British Journal of Cancer, 2013, 109, 318-324.	6.4	80
184	Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma-In Situ Treated with Mastectomy: Is Further Therapy Warranted?. Annals of Surgical Oncology, 2013, 20, 4103-4112.	1.5	48
185	Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Annals of Oncology, 2013, 24, 2515-2521.	1.2	36
186	TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Research, 2013, 73, 6516-6525.	0.9	70
187	Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma. SpringerPlus, 2013, 2, 409.	1.2	21
188	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Research, 2013, 15, R112.	5.0	46
189	Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets. Clinical Cancer Research, 2013, 19, 4685-4696.	7.0	130
190	Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Research and Treatment, 2013, 138, 761-772.	2.5	56
191	Accelerated partial-breast irradiation using intensity-modulated proton radiotherapy: do uncertainties outweigh potential benefits?. British Journal of Radiology, 2013, 86, 20130176.	2.2	23
192	Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Annals of Oncology, 2013, 24, 1999-2004.	1.2	65
193	Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency. Breast Cancer Research, 2013, 15, R77.	5.0	60
194	The Antihelmintic Drug Pyrvinium Pamoate Targets Aggressive Breast Cancer. PLoS ONE, 2013, 8, e71508.	2.5	46
195	Human Omental-Derived Adipose Stem Cells Increase Ovarian Cancer Proliferation, Migration, and Chemoresistance. PLoS ONE, 2013, 8, e81859.	2.5	95
196	Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. ELife, 2013, 2, e00996.	6.0	42
197	Identifying factors that impact survival among women with inflammatory breast cancer. Annals of Oncology, 2012, 23, 870-875.	1.2	42
198	The Value of Ultrasound in Detecting Extra-Axillary Regional Node Involvement in Patients With Advanced Breast Cancer. Oncologist, 2012, 17, 1402-1408.	3.7	24

#	Article	IF	CITATIONS
199	Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist, 2012, 17, 891-899.	3.7	127
200	Cardiac Motion During Deep-Inspiration Breath-Hold: Implications for Breast Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 708-714.	0.8	47
201	Topical Hyaluronic Acid vs. Standard of Care for the Prevention of Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer: Single-Blind Randomized Phase III Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1089-1094.	0.8	65
202	Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients WithÂInflammatory Breast Cancer Influences RadiationÂTreatment Field Designs. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1381-1386.	0.8	42
203	In Reply to Drs. Pergolizzi and Santacaterina. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1059.	0.8	0
204	Current clinical coverage of Radiation Therapy Oncology Group-defined target volumes for postmastectomy radiation therapy. Practical Radiation Oncology, 2012, 2, 201-209.	2.1	30
205	Omental Adipose Tissue–Derived Stromal Cells Promote Vascularization and Growth of Endometrial Tumors. Clinical Cancer Research, 2012, 18, 771-782.	7.0	151
206	Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/β atenin Signaling. Stem Cells, 2012, 30, 2366-2377.	3.2	100
207	Field match verification during combination proton, photon, and electron therapy for oligometastatic inflammatory breast cancer. Medical Dosimetry, 2012, 37, 442-444.	0.9	2
208	Detection of Canonical Hedgehog Signaling in Breast Cancer by 131-lodine-Labeled Derivatives of the Sonic Hedgehog Protein. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-8.	3.0	13
209	Cell Gene Expression Signatures in Inflammatory Breast Cancer. , 2012, , 259-270.		0
210	Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer, 2012, 118, 4936-4943.	4.1	25
211	Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Research and Treatment, 2012, 134, 495-510.	2.5	56
212	Models of Inflammatory Breast Cancer. , 2012, , 139-150.		5
213	Radiation Therapy for Inflammatory Breast Cancer. , 2012, , 75-84.		1
214	International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of Oncology, 2011, 22, 515-523.	1.2	407
215	Automating RTOG-defined target volumes for postmastectomy radiation therapy. Practical Radiation Oncology, 2011, 1, 97-104.	2.1	4
216	Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44+CD24lo cancer stem cell phenotype. European Journal of Cancer, 2011, 47, 1527-1536.	2.8	89

#	Article	IF	CITATIONS
217	Local-Regional Recurrence With and Without Radiation Therapy After Neoadjuvant Chemotherapy and Mastectomy for Clinically Staged T3N0 Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 782-787.	0.8	64
218	The Impact of Age on Outcome in Early-Stage Breast Cancer. Seminars in Radiation Oncology, 2011, 21, 26-34.	2.2	70
219	EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling. Cancer Cell, 2011, 19, 86-100.	16.8	371
220	BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. Cancer Cell, 2011, 20, 341-356.	16.8	67
221	Age and Survival Estimates in Patients Who Have Node-Negative T1ab Breast Cancer by Breast Cancer Subtype. Clinical Breast Cancer, 2011, 11, 325-331.	2.4	62
222	Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation. Annals of Surgical Oncology, 2011, 18, 3164-3173.	1.5	93
223	Should breast conservation be offered to young women with breast cancer?. Breast Cancer Research and Treatment, 2011, 127, 217-219.	2.5	1
224	Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Research and Treatment, 2011, 125, 785-795.	2.5	68
225	Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Research and Treatment, 2011, 128, 421-427.	2.5	11
226	Breast Preservation in Patients with Local Recurrence After Breast-Conserving Therapy. Current Breast Cancer Reports, 2011, 3, 88-96.	1.0	2
227	Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early. Cancer, 2011, 117, 1819-1826.	4.1	121
228	Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptorâ€positive progesterone receptorâ€positive disease in very early stage breast cancer. Cancer, 2011, 117, 1595-1601.	4.1	12
229	Long-Term Outcomes in Patients With Isolated Supraclavicular Nodal Recurrence After Mastectomy and Doxorubicin-Based Chemotherapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1453-1457.	0.8	20
230	External-Beam Accelerated Partial Breast Irradiation Using Multiple Proton Beam Configurations. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1464-1472.	0.8	43
231	Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist, 2011, 16, 1675-1683.	3.7	86
232	Tetrandrine, a Compound Common in Chinese Traditional Medicine, Preferentially Kills Breast Cancer Tumor Initiating Cells (TICs) In Vitro. Cancers, 2011, 3, 2274-2285.	3.7	33
233	Breast cancer stem cell targets. Oncology, 2011, 25, 34, 36.	0.5	1
234	Clinically Apparent Internal Mammary Nodal Metastasis in Patients With Advanced Breast Cancer: Incidence and Local Control. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1113-1119.	0.8	51

#	Article	IF	CITATIONS
235	Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Research and Treatment, 2010, 123, 597-605.	2.5	8
236	Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. Ca-A Cancer Journal for Clinicians, 2010, 60, 351-375.	329.8	298
237	Racial disparities in the use of radiotherapy after breastâ€conserving surgery: A national Medicare study. Cancer, 2010, 116, 734-741.	4.1	82
238	Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy. Cancer, 2010, 116, 3084-3092.	4.1	31
239	Overcoming radiation resistance in inflammatory breast cancer. Cancer, 2010, 116, 2840-2845.	4.1	25
240	Suberoylanilide hydroxamic acid blocks selfâ€renewal and homotypic aggregation of inflammatory breast cancer spheroids. Cancer, 2010, 116, 2760-2767.	4.1	25
241	Populationâ€based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer, 2010, 116, 4000-4006.	4.1	85
242	Differential Radiosensitizing Effect of Valproic Acid in Differentiation Versus Self-Renewal Promoting Culture Conditions. International Journal of Radiation Oncology Biology Physics, 2010, 76, 889-895.	0.8	39
243	Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1296-1302.	0.8	79
244	Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast Journal, 2010, 16, 529-532.	1.0	24
245	Imaging and Analysis of 3D Tumor Spheroids Enriched for a Cancer Stem Cell Phenotype. Journal of Biomolecular Screening, 2010, 15, 820-829.	2.6	58
246	Incidence of and survival following brain metastases among women with inflammatory breast cancer. Annals of Oncology, 2010, 21, 2348-2355.	1.2	29
247	Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast Cells. PLoS ONE, 2010, 5, e12180.	2.5	148
248	Magnetically-Responsive Nanoparticles for Vectored Delivery of Cancer Therapeutics. AIP Conference Proceedings, 2010, , .	0.4	5
249	Potential Targets for Improving Radiosensitivity of Breast Tumor-Initiating Cells. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 152-156.	1.7	2
250	The Importance of Targeting Cancer Stem Cells in Breast Cancer Treatment. Breast Diseases, 2010, 21, 23-25.	0.0	0
251	Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Molecular Cancer, 2010, 9, 180.	19.2	66
252	The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resistance Updates, 2010, 13, 99-108.	14.4	70

#	Article	IF	CITATIONS
253	Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation. Radiotherapy and Oncology, 2010, 95, 312-316.	0.6	21
254	Thermal Enhancement with Optically Activated Gold Nanoshells Sensitizes Breast Cancer Stem Cells to Radiation Therapy. Science Translational Medicine, 2010, 2, 55ra79.	12.4	167
255	Isolation of Oct4-Expressing Extraembryonic Endoderm Precursor Cell Lines. PLoS ONE, 2009, 4, e7216.	2.5	50
256	Coexpression of α6β4 Integrin and Guanine Nucleotide Exchange Factor Net1 Identifies Node-Positive Breast Cancer Patients at High Risk for Distant Metastasis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 80-86.	2.5	41
257	Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer. American Journal of Surgical Pathology, 2009, 33, 759-767.	3.7	85
258	Radiosensitivity of Cancer-Initiating Cells and Normal Stem Cells (or what the Heisenberg Uncertainly) Tj ETQq0 (0 0 rgBT /C)verlock 10 T
259	Inflammatory Breast Cancer. Seminars in Radiation Oncology, 2009, 19, 256-265.	2.2	62
260	The impact of pregnancy on breast cancer outcomes in women â‰ 8 5 years. Cancer, 2009, 115, 1174-1184.	4.1	154
261	Radiation Resistance of Breast Cancer Stem Cells: Understanding the Clinical Framework. Journal of Mammary Gland Biology and Neoplasia, 2009, 14, 11-17.	2.7	46
262	Therapeutic strategies to eliminate breast cancer stem cells. Current Breast Cancer Reports, 2009, 1, 222-228.	1.0	2
263	The Effect of Adjuvant Radiotherapy on Mortality Differs According to Primary Tumor Location in Women with Node-Positive Breast Cancer. Strahlentherapie Und Onkologie, 2009, 185, 161-168.	2.0	13
264	Effects of Variable Placement of Superior Tangential/Supraclavicular Match Line on Dosimetric Coverage of Level III Axilla/Axillary Apex in Patients Treated With Breast and Supraclavicular Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 370-374.	0.8	14
265	Ten-Year Recurrence Rates in Young Women With Breast Cancer by Locoregional Treatment Approach. International Journal of Radiation Oncology Biology Physics, 2009, 73, 734-744.	0.8	83
266	Automatic Segmentation of Whole Breast Using Atlas Approach and Deformable Image Registration. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1493-1500.	0.8	102
267	Variability of Target and Normal Structure Delineation for Breast Cancer Radiotherapy: An RTOG Multi-Institutional and Multiobserver Study. International Journal of Radiation Oncology Biology Physics, 2009, 73, 944-951.	0.8	321
268	Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. Journal of Experimental and Clinical Cancer Research, 2009, 28, 67.	8.6	35
269	Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Annals of Oncology, 2009, 20, 1953-1958.	1.2	268
270	Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncology, 2009, 5, 1585-1603.	2.4	51

#	Article	IF	CITATIONS
271	Cancer stem cells: markers or biomarkers?. Cancer and Metastasis Reviews, 2008, 27, 459-470.	5.9	102
272	Prospective analysis of carotid artery flow in breast cancer patients treated with supraclavicular irradiation 8 or more years previously. Cancer, 2008, 112, 268-273.	4.1	17
273	Risk of hypothyroidism in older breast cancer patients treated with radiation. Cancer, 2008, 112, 1371-1379.	4.1	58
274	Risk of Subclinical Micrometastatic Disease in the Supraclavicular Nodal Bed According to the Anatomic Distribution in Patients With Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 435-440.	0.8	38
275	Radiation Use and Long-Term Survival in Breast Cancer Patients With T1, T2 Primary Tumors and One to Three Positive Axillary Lymph Nodes. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1022-1027.	0.8	29
276	Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 474-484.	0.8	130
277	The Role of Locoregional Therapy in Inflammatory Breast Cancer. Seminars in Oncology, 2008, 35, 78-86.	2.2	33
278	The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. European Journal of Cancer, 2008, 44, 1670-1677.	2.8	97
279	4–40 Prognosis of Breast Cancer After Supraclavicular Lymph Node Metastasis: Not a Distant Metastasis. Breast Diseases, 2008, 18, 388.	0.0	0
280	Cerebrovascular Disease Risk in Older Head and Neck Cancer Patients After Radiotherapy. Journal of Clinical Oncology, 2008, 26, 5119-5125.	1.6	206
281	The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response. Expert Opinion on Medical Diagnostics, 2008, 2, 339-348.	1.6	10
282	Molecular Basis of Radiation Therapy. , 2008, , 593-604.		2
283	Leukemia-Associated Primary Granule Proteins (PGPs) Elastase-2 and Proteinase-3 Are Aberrantly Expressed in Solid Tumors: A Potential Therapeutic Target for PR1-Directed Immunotherapy. Blood, 2008, 112, 5440-5440.	1.4	1
284	Tumor Irradiation Increases the Recruitment of Circulating Mesenchymal Stem Cells into the Tumor Microenvironment. Cancer Research, 2007, 67, 11687-11695.	0.9	273
285	Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 1888-1889.	27.0	6
286	Multileaf field-in-field forward-planned intensity-modulated dose compensation for whole-breast irradiation is associated with reduced contralateral breast dose: A phantom model comparison. Radiotherapy and Oncology, 2007, 82, 324-328.	0.6	54
287	WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proceedings of the United States of America, 2007, 104, 618-623.	7.1	599
288	Local Recurrence of Breast Cancer After MammoSite® Brachytherapy. Breast Diseases, 2007, 18, 195.	0.0	0

#	Article	IF	CITATIONS
289	Wnt/β-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. Journal of Cell Science, 2007, 120, 468-477.	2.0	170
290	Primary angiosarcomas of the breast. Cancer, 2007, 110, 173-178.	4.1	137
291	Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer, 2007, 110, 2420-2427.	4.1	93
292	Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. International Journal of Radiation Oncology Biology Physics, 2007, 67, 490-496.	0.8	33
293	The Ratio of Positive to Excised Nodes Identifies High-risk Subsets and Reduces Inter-Institutional Differences in Locoregional Recurrence Risk Estimates in Breast Cancer Patients With 1–3 Positive Nodes: An Analysis of Prospective Data From British Columbia and the M. D. Anderson Cancer Center.	0.8	73
294	Postmastectomy Radiation Improves the Outcome of Patients With Locally Advanced Breast Cancer Who Achieve a Pathologic Complete Response to Neoadjuvant Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1004-1009.	0.8	229
295	Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1478-1483.	0.8	45
296	Treatment Optimization Using Computed Tomography-Delineated Targets Should be Used for Supraclavicular Irradiation for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 711-715.	0.8	30
297	Should post-mastectomy radiation be used for node-negative breast cancer patients?. Women's Oncology Review, 2007, 6, 81-82.	0.0	1
298	Post-mastectomy radiation for breast cancer patients with small tumors and one to three positive lymph nodes. Women's Oncology Review, 2007, 6, 79-80.	0.0	1
299	The Importance of Radiation Therapy in Improving Survival of Selected Patients with Breast Cancer. Breast Diseases, 2006, 17, 208-210.	0.0	Ο
300	Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1155-1160.	0.8	13
301	Supraclavicular radiation for breast cancer does not increase the 10-year risk of stroke. Cancer, 2006, 106, 2556-2562.	4.1	39
302	African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer, 2006, 107, 2662-2668.	4.1	46
303	Optimizing locoregional control and survival for women with breast cancer: a review of current developments in postmastectomy radiotherapy. Expert Review of Anticancer Therapy, 2006, 6, 205-216.	2.4	11
304	Locoregional Control of Clinically Diagnosed Multifocal or Multicentric Breast Cancer After Neoadjuvant Chemotherapy and Locoregional Therapy. Journal of Clinical Oncology, 2006, 24, 4971-4975.	1.6	68
305	Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer. Journal of Clinical Oncology, 2006, 24, 2910-2916.	1.6	178
306	Angiosarcoma of the breast. Journal of Clinical Oncology, 2006, 24, 9554-9554.	1.6	1

#	Article	IF	CITATIONS
307	Should post-mastectomy radiation be used for node-negative breast cancer patients?. Women's Oncology Review, 2006, 6, 81-82.	0.0	Ο
308	Clinical investigation: Regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1508-1513.	0.8	92
309	Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade. Prostate Cancer and Prostatic Diseases, 2005, 8, 127-132.	3.9	16
310	On mammary stem cells. Journal of Cell Science, 2005, 118, 3585-3594.	2.0	233
311	Anthracyclines and breast radiotherapy: the need for prospective evaluation. International Journal of Radiation Oncology Biology Physics, 2004, 59, 319-320.	0.8	0
312	In reply to Dr. Monsour. International Journal of Radiation Oncology Biology Physics, 2004, 60, 687-688.	0.8	1
313	In reply to Drs. Madhavan and Pervez. International Journal of Radiation Oncology Biology Physics, 2004, 59, 320.	0.8	1
314	Cardiovascular death and second non–breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 327-335.	0.8	54
315	Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. International Journal of Radiation Oncology Biology Physics, 2003, 57, 336-344.	0.8	87
316	Changes in the 2003 American Joint Committee on Cancer Staging for Breast Cancer Dramatically Affect Stage-Specific Survival. Journal of Clinical Oncology, 2003, 21, 3244-3248.	1.6	135
317	7. Long-Term Toxicity after Postmastectomy Radiation and Doxorubicin-Based Chemotherapy. Cancer Journal (Sudbury, Mass), 2003, 9, 486.	2.0	0
318	N-Cadherin expression and signaling in limb mesenchymal chondrogenesis: Stimulation by Poly-l-Lysine. , 1999, 24, 178-187.		44
319	Accurate whole-spectrum measurements of intracellular pH and [Na+]. Journal of Fluorescence, 1995, 5, 329-335.	2.5	13
320	Crystal structures of 30-crown-10 and its tetrahydrate. Journal of Organic Chemistry, 1994, 59, 1694-1702.	3.2	29
321	Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Annals of Surgical Oncology, 0, , .	1.5	2